Inventor · disambiguated record
William Brondyk
Also filed as: BRONDYK WILLIAM · BRONDYK WILLIAM H · BRONDYK WILLIAM HAROLD
19 granted patents·25 pending applications·42 citations·filing 2002–2025
92Inventor score
Top patents by PatentIndex Score
44 records- 0194US11498953B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2021·Granted Nov 15, 2022·6 cites·21 claims
- 0291US11434276B2Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of useINVETX INC·Filed 2021·Granted Sep 6, 2022·2 cites·13 claims
- 0390US11739135B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2022·Granted Aug 29, 2023·1 cites·9 claims
- 0487US8617554B2Anti-human CD52 immunoglobulinsROBERTS BRUCE L·Filed 2010·Granted Dec 31, 2013·16 cites·44 claims
- 0585US2024166749A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0685US2024239896A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0785US2024166748A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0885US2024239897A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0984US10626169B2Multispecific binding molecules having specificity to dystroglycan and laminin-2SANOFI SA·Filed 2018·Granted Apr 21, 2020·8 cites·17 claims
- 1081US2023279118A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2022·Application pending·0 cites
- 1180US2025304650A1Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2025·Application pending·0 cites
- 1279US12344650B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2022·Granted Jul 1, 2025·0 cites·18 claims
- 1379US2023322873A1Methods to produce rod-derived cone viability factor (rdcvf)GENZYME CORP·Filed 2022·Application pending·0 cites
- 1477US12378308B2Anti-NGF antibodies and uses thereofINVETX INC·Filed 2024·Granted Aug 5, 2025·0 cites·27 claims
- 1577US2024327497A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 1675US12110322B2Anti-NGF antibodies and uses thereofINVETX INC·Filed 2023·Granted Oct 8, 2024·0 cites·30 claims
- 1775US10035829B2Methods to produce rod-derived cone viability factor (RDCVF)GENZYME CORP·Filed 2017·Granted Jul 31, 2018·1 cites·15 claims
- 1875US2025197478A1Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 1974US11945874B2Anti-human CD52 immunoglobulinsGENZYME CORP·Filed 2021·Granted Apr 2, 2024·0 cites·17 claims
- 2071US11542333B2Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2020·Granted Jan 3, 2023·0 cites·9 claims
- 2171US7258997B2Methods of increasing protein expression levelsAPPLIED RESEARCH SYSTEMS·Filed 2002·Granted Aug 21, 2007·2 cites·5 claims
- 2271US2023127241A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2022·Application pending·0 cites
- 2370US11548949B2Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2020·Granted Jan 10, 2023·0 cites·7 claims
- 2469US2025011410A1Anti-ngf antibodies and uses thereofINVETX INC·Filed 2022·Application pending·0 cites
- 2568US9567382B2Methods to produce rod-derived cone viability factor (RdCVF)O'RIORDAN CATHERINE R·Filed 2009·Granted Feb 14, 2017·1 cites·16 claims
- 2667US7317095B2Mutant glycoproteinsAPPLIED RESEARCH SYSTEMS·Filed 2002·Granted Jan 8, 2008·3 cites·23 claims
- 2767US2024209096A1Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of useINVETX INC·Filed 2023·Application pending·0 cites
- 2867US2024209062A1Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of useINVETX INC·Filed 2023·Application pending·0 cites
- 2966US2025188176A1Anti-il-4ra antibodies and uses thereofINVETX INC·Filed 2024·Application pending·0 cites
- 3065US12103961B2Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of useINVETX INC·Filed 2021·Granted Oct 1, 2024·0 cites·28 claims
- 3165US11505611B2FGFR3 antibodies and methods of useGENZYME CORP·Filed 2021·Granted Nov 22, 2022·0 cites·16 claims
- 3265US2025051435A1Anti-il-5 antibodies and uses thereofINVETX INC·Filed 2024·Application pending·0 cites
- 3365US2023303704A1Fgfr3 antibodies and methods of useGENZYME CORP·Filed 2022·Application pending·0 cites
- 3463US7700112B2FSH beta mutants that are glycosilated at residues N55 and T57MERCK SERONO SA·Filed 2004·Granted Apr 20, 2010·2 cites·12 claims
- 3562US2020040091A1Anti-Human CD52 ImmunoglobulinsGENZYME CORP·Filed 2019·Application pending·0 cites
- 3659US2019055293A1Methods to produce rod-derived cone viability factor (rdcvf)GENZYME CORP·Filed 2018·Application pending·0 cites
- 3759US2014341910A1Anti-human cd52 immunoglobulinsGENZYME CORP·Filed 2013·Application pending·0 cites
- 3852US2016208010A1Anti-human cd52 immunoglobulinsGENZYME CORP·Filed 2015·Application pending·0 cites
- 3947US2025257142A1Anti-il-31ra antibodies and uses thereofINVETX INC·Filed 2025·Application pending·0 cites
- 4045US11254737B2Multispecific binding molecules having specificity to dystroglycan and laminin-2SANOFI SA·Filed 2020·Granted Feb 22, 2022·0 cites·38 claims
- 4145US2018214542A1Humanized cxcr3 antibodies with depleting activity and methods of use thereofSANOFI SA·Filed 2017·Application pending·0 cites
- 4241US2004198799A1Methods of increasing endogenous testosterone levelsFiled 2002·Application pending·0 cites
- 4340US2018244787A1Anti-human cxcr3 antibodies for treatment of vitiligoSANOFI SA·Filed 2017·Application pending·0 cites
- 4432US2008014635A1Methods of increasing protein expression levelsBRONDYK WILLIAM·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when William Brondyk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →